New biotech looks to prevent hair loss from chemotherapy

Though in early stages, an antibody being developed by Perseus Therapeutics shows promise in preventing the common chemotherapy side effect.

January 17, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it Though in early stages, an antibody being developed by Perseus Therapeutics shows promise in preventing this common chemotherapy side effect. By Angus Chen STAT+ | At health care's biggest investor conference, AI's high hopes collided with skepticism Generative AI was prominently featured at the J.P. Morgan Healthcare Conference, but not everybody was convinced of its near-term value. By Casey Ross and Matthew Herper and Mohana Ravindranath STAT+ | General Catalyst to buy Ohio-based health system Summa Health VC firm General Catalyst has agreed to buy Ohio-based nonprofit health system Summa Health and reestablish it as a for-profit organization By Mohana Ravindranath Mike Reddy for STAT STAT+ | More patients are getting their meds online. Big Pharma wants in on the action A partnership between LillyDirect and online pharmacy Truepill becomes an industry model, as drugmakers expand direct-to-consumer marketing. By Katie Palmer STAT+ | Copay coupons for some drugs must count toward deductibles, after Biden court move Biden drops defense of Trump copay accumulator rule that aimed to curb drug prices but raised patient costs. By John Wilkerson STAT+ | FDA clears AI skin cancer detector for primary care doctors to use The Food and Drug Administration cleared an AI-powered medical device for detecting skin cancer on Wednesday. By Lizzy Lawrence Sandy Huffaker/Getty Images A new, non-invasive test could help predict the quality of embryo used for IVF UC San Diego researchers say a new, non-invasive test can predict the quality of embryos used for in vitro fertilization. By Deborah Balthazar Opinion: The decline and fall of elite multispecialty medical groups The failure of elite multispecialty medical groups like Geisinger is an indictment of federal physician payment policy. By Jeff Goldsmith

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser